Journal
NATURE MEDICINE
Volume 15, Issue 5, Pages 528-536Publisher
NATURE PORTFOLIO
DOI: 10.1038/nm.1953
Keywords
-
Funding
- Canadian Institute for Health
- Ontario Institute for Cancer Research
- Terry Fox Cancer Foundation National Cancer Institute of Canada
- Boninchi Foundation (Geneva, Switzerland)
- National Cancer Institute of Canada
- Cancer Research Institute (New York)
Ask authors/readers for more resources
Identifying key factors that enhance immune responses is crucial for manipulating immunity to tumors. We show that after a vaccine-induced immune response, adjuvant interleukin-7 (IL-7) improves antitumor responses and survival in an animal model. The improved immune response is associated with increased IL-6 production and augmented T helper type 17 cell differentiation. Furthermore, IL-7 modulates the expression of two ubiquitin ligases: Casitas B-lineage lymphoma b (Cbl-b), a negative regulator of T cell activation, is repressed, and SMAD-specific E3 ubiquitin protein ligase-2 (Smurf2) is enhanced, which antagonizes transforming growth factor-beta signaling. Notably, we show that although short term IL-7 therapy potently enhances vaccine-mediated immunity, in the absence of vaccination it is inefficient in promoting antitumor immune responses, despite inducing homeostatic proliferation of T cells. The ability of adjuvant IL-7 to antagonize inhibitory networks at the cellular and molecular level has major implications for immunotherapy in the treatment of tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available